Citigroup Cuts Qiagen (NYSE:QGEN) Price Target to $55.00

Qiagen (NYSE:QGEN) had its target price trimmed by Citigroup from $55.40 to $55.00 in a research report released on Friday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Other equities analysts have also issued research reports about the stock. TD Cowen reiterated a “hold” rating on shares of Qiagen in a report on Friday. UBS Group reiterated a “neutral” rating on shares of Qiagen in a report on Wednesday, January 21st. Stifel Nicolaus set a $50.00 price target on Qiagen and gave the stock a “hold” rating in a research note on Friday. Deutsche Bank Aktiengesellschaft downgraded Qiagen from a “buy” rating to a “hold” rating and raised their price objective for the stock from $52.00 to $54.00 in a report on Thursday, January 22nd. Finally, Wall Street Zen cut Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. Four equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $55.27.

Qiagen Stock Down 0.3%

QGEN stock opened at $51.08 on Friday. The company has a current ratio of 2.60, a quick ratio of 2.30 and a debt-to-equity ratio of 0.45. The company’s 50-day moving average price is $49.65 and its 200 day moving average price is $49.63. Qiagen has a 52 week low of $39.61 and a 52 week high of $57.81. The company has a market cap of $10.79 billion, a P/E ratio of 25.33, a P/E/G ratio of 2.54 and a beta of 0.67.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.01. Qiagen had a return on equity of 14.82% and a net margin of 20.33%.The business had revenue of $540.42 million during the quarter, compared to analysts’ expectations of $528.53 million. During the same quarter last year, the business posted $0.61 earnings per share. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, research analysts expect that Qiagen will post 2.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Danske Bank A S acquired a new stake in Qiagen in the third quarter worth $36,000. Smartleaf Asset Management LLC raised its holdings in shares of Qiagen by 1,383.3% during the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after buying an additional 830 shares during the last quarter. MAI Capital Management boosted its position in shares of Qiagen by 998.9% during the second quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after buying an additional 889 shares during the period. Global Retirement Partners LLC boosted its position in shares of Qiagen by 279.9% during the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after buying an additional 851 shares during the period. Finally, Allworth Financial LP grew its holdings in Qiagen by 260.1% in the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after buying an additional 796 shares in the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: JPMorgan raised its price target to $60 and set an “overweight” rating, signaling ~17.5% upside from current levels. This analyst upgrade is a near-term bullish catalyst. Article Title
• Positive Sentiment: Unusually large options activity: traders bought ~40,639 call options (a ~4,600% increase vs. average), suggesting some investors are positioning for upside. (no article link provided)
• Positive Sentiment: Management reiterated a sales-growth target (at least ~5% sales growth for 2026), which supports topline momentum assumptions even as profitability is pressured. Article Title
• Neutral Sentiment: Citigroup trimmed its target slightly to $55 and moved to “neutral” — a modest calibration rather than a stark downgrade; this tempers but does not reverse bullish signals. Article Title Ticker Report
• Neutral Sentiment: Q4 results: EPS roughly in line ($0.62, vs. $0.61 consensus) and revenue modestly beat — evidence of steady demand but not a breakout. Zacks Earnings Article
• Neutral Sentiment: Full earnings materials and call transcript are available for deeper read‑throughs (slides, call transcript) — useful for investors assessing guidance drivers and margin details. Press Release Earnings Transcript
• Negative Sentiment: Guidance disappointed: Q1 EPS guidance (~$0.54) and FY‑2026 EPS (≈$2.50) were below Street consensus, which pressured sentiment as investors focus on margin recovery and near‑term profitability. Press Release
• Negative Sentiment: Margin contraction noted in coverage: analysts and news pieces flagged margin pressure and cautious tone on 2026, which was a primary reason the stock sold off despite the top‑line beat. Zacks Margin Article

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.